South Korea's Samsung Biologics signs $231 million supply deal with GSK
Published
South Korean contract drugs manufacturer Samsung Biologics Co Ltd said on Friday it had signed a deal worth more than $231 million with GlaxoSmithKline PLC (GSK) to supply biopharmaceutical products over the next eight years.
Full Article